Diabetes Medication Market: Costs and Utilization of Glucagon-Like Peptide 1 (GLP-1) Prescriptions From 2008 to 2023

IF 5.9 2区医学 Q2 ENDOCRINOLOGY & METABOLISM

Journal of Diabetes Pub Date : 2026-10-08 DOI:10.1111/1753-0407.70278

Kaili Mauricio, Brielle Ruscitti, Andrew White, Diana Bowser

引用次数: 0

Abstract

The figure shows the market share of prescriptions filled from 2008 to 2023. Over this period, the GLP-1 prescription market shifted from predominantly Byetta to a broader distribution across Victoza, Trulicity, and Ozempic, with smaller shares of Rybelsus and Mounjaro by 2023.

查看原文本刊更多论文

糖尿病药物市场：2008 - 2023年胰高血糖素样肽1 （GLP-1）处方的成本和利用

该图显示了2008年至2023年处方的市场份额。在此期间，GLP-1处方市场从主要的Byetta转变为Victoza、Trulicity和Ozempic的更广泛分布，到2023年，Rybelsus和Mounjaro的份额将减少。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Diabetes ENDOCRINOLOGY & METABOLISM-

CiteScore

6.50

自引率

2.20%

发文量

审稿时长

>12 weeks

期刊介绍： Journal of Diabetes (JDB) devotes itself to diabetes research, therapeutics, and education. It aims to involve researchers and practitioners in a dialogue between East and West via all aspects of epidemiology, etiology, pathogenesis, management, complications and prevention of diabetes, including the molecular, biochemical, and physiological aspects of diabetes. The Editorial team is international with a unique mix of Asian and Western participation. The Editors welcome submissions in form of original research articles, images, novel case reports and correspondence, and will solicit reviews, point-counterpoint, commentaries, editorials, news highlights, and educational content.